Folliculotropic mycosis fungoides

Summary

Folliculotropic mycosis fungoides (MONDO:0015808) is a disease and 4 clinical trials. Top therapeutic interventions include durvalumab, mechlorethamine hydrochloride, and mogamulizumab. A subtype of secondary catabolic mucinosis of skin — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	folliculotropic mycosis fungoides
Mondo ID	MONDO:0015808
Orphanet	178512
ICD-11	1335995469
NCIT	C35685
SNOMED CT	404109006
UMLS	C1627767
MedGen	302080
GARD	0020154
Is cancer (heuristic)	no

Also known as: follicular mucinosis type mycosis fungoides · follicular mycosis fungoides · folliculotropic mycosis fungoides · mycosis fungoides-associated follicular mucinosis

Disease family

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › cutaneous mucinosis › secondary catabolic mucinosis of skin › folliculotropic mycosis fungoides

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03011814	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
NCT04930653	PHASE2	RECRUITING	Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
NCT03380026	PHASE2	COMPLETED	Mechlorethamine Induced Contact Dermatitis Avoidance Study
NCT03373305	PHASE1	WITHDRAWN	Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DURVALUMAB	4	1
MECHLORETHAMINE HYDROCHLORIDE	4	1
MOGAMULIZUMAB	4	1
TRIAMCINOLONE	4	1